IL262251B2 - New anti-syrap antibodies and their medical applications - Google Patents

New anti-syrap antibodies and their medical applications

Info

Publication number
IL262251B2
IL262251B2 IL262251A IL26225118A IL262251B2 IL 262251 B2 IL262251 B2 IL 262251B2 IL 262251 A IL262251 A IL 262251A IL 26225118 A IL26225118 A IL 26225118A IL 262251 B2 IL262251 B2 IL 262251B2
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Application number
IL262251A
Other languages
English (en)
Hebrew (he)
Other versions
IL262251A (en
IL262251B1 (en
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Vanessa Gauttier
Virginie Thepenier
Sabrina Pengam
Original Assignee
Ose Immunotherapeutics
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Vanessa Gauttier
Virginie Thepenier
Sabrina Pengam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics, Nicolas Poirier, Caroline Mary, Bernard Vanhove, Vanessa Gauttier, Virginie Thepenier, Sabrina Pengam filed Critical Ose Immunotherapeutics
Priority claimed from PCT/EP2017/059071 external-priority patent/WO2017178653A2/en
Publication of IL262251A publication Critical patent/IL262251A/en
Publication of IL262251B1 publication Critical patent/IL262251B1/en
Publication of IL262251B2 publication Critical patent/IL262251B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL262251A 2016-04-14 2017-04-14 New anti-syrap antibodies and their medical applications IL262251B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
EP17305182 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Publications (3)

Publication Number Publication Date
IL262251A IL262251A (en) 2018-11-29
IL262251B1 IL262251B1 (en) 2023-05-01
IL262251B2 true IL262251B2 (en) 2023-09-01

Family

ID=65529144

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262251A IL262251B2 (en) 2016-04-14 2017-04-14 New anti-syrap antibodies and their medical applications

Country Status (24)

Country Link
US (3) US11279766B2 (enExample)
EP (1) EP4438626A3 (enExample)
JP (2) JP7491666B2 (enExample)
KR (1) KR102355240B1 (enExample)
CN (1) CN115785272A (enExample)
CL (1) CL2018002898A1 (enExample)
DK (1) DK3443010T3 (enExample)
ES (1) ES2990971T3 (enExample)
FI (1) FI3443010T3 (enExample)
HR (1) HRP20241316T1 (enExample)
HU (1) HUE068840T2 (enExample)
IL (1) IL262251B2 (enExample)
LT (1) LT3443010T (enExample)
MA (1) MA44665B1 (enExample)
MD (1) MD3443010T2 (enExample)
MX (1) MX2018012434A (enExample)
PH (1) PH12018550160B1 (enExample)
PL (1) PL3443010T3 (enExample)
RS (1) RS66062B1 (enExample)
SA (1) SA518400237B1 (enExample)
SI (1) SI3443010T1 (enExample)
SM (1) SMT202400438T1 (enExample)
UA (1) UA126658C2 (enExample)
ZA (1) ZA201806293B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012434A (es) * 2016-04-14 2019-06-06 Ose Immunotherapeutics Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas.
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2018308364C1 (en) * 2017-07-26 2023-02-16 Forty Seven, LLC Anti-SIRP-alpha antibodies and related methods
US11713356B2 (en) * 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法
CN118344481A (zh) 2018-03-21 2024-07-16 Alx肿瘤生物技术公司 针对信号调控蛋白α的抗体和使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MX2021003393A (es) 2018-09-27 2021-05-13 Celgene Corp Proteinas de fijacion a sirp alfa y metodos de uso de estas.
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120039896A1 (en) * 2003-04-24 2012-02-16 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
US20100239578A1 (en) 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA2702083C (en) 2007-10-12 2021-11-30 Massachusetts Institute Of Technology Vaccine nanotechnology
DK2242512T3 (en) 2008-01-15 2016-06-06 Univ Leland Stanford Junior Method for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
FI2995315T3 (fi) 2009-05-15 2024-03-18 Univ Health Network Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
EP2701722A4 (en) 2011-04-28 2014-12-31 Univ Southern California Human myeloid derived suppressor cell cancer markers
CN103635490A (zh) * 2011-06-16 2014-03-12 诺瓦提斯公司 用作治疗剂的可溶性蛋白
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
EP2953643B1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
JP7078533B2 (ja) 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物
MX2018012434A (es) 2016-04-14 2019-06-06 Ose Immunotherapeutics Nuevos anticuerpos anti-sirpa y sus aplicaciones terapeuticas.
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
EA201891882A1 (ru) 2017-02-17 2019-07-31 Осе Иммьюнотерапьютикс НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ
TW202430219A (zh) * 2017-04-13 2024-08-01 荷蘭商賽羅帕公司 抗-SIRPα 抗體
PL3625259T3 (pl) 2017-05-16 2024-08-12 Byondis B.V. Przeciwciała anty-sirpalfa
AU2018308364C1 (en) 2017-07-26 2023-02-16 Forty Seven, LLC Anti-SIRP-alpha antibodies and related methods
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法
CN118344481A (zh) 2018-03-21 2024-07-16 Alx肿瘤生物技术公司 针对信号调控蛋白α的抗体和使用方法
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
CA3219158A1 (en) 2018-07-10 2020-01-16 National University Corporation Kobe University Anti-sirp.alpha. antibody
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
MX2021003393A (es) 2018-09-27 2021-05-13 Celgene Corp Proteinas de fijacion a sirp alfa y metodos de uso de estas.
CN113573728A (zh) 2018-11-14 2021-10-29 安驰肿瘤公司 治疗性SIRPα抗体
JP7451520B2 (ja) 2018-11-15 2024-03-18 ビョンディス・ビー．ブイ． ヒト化抗ＳＩＲＰα抗体
EP3969476A1 (en) 2019-03-04 2022-03-23 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
JP2022545300A (ja) 2019-08-20 2022-10-27 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｓｉｒｐａ抗体
CN111635458A (zh) 2020-03-20 2020-09-08 上海健信生物医药科技有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术（南京）有限公司 一种抗人SIRPα单克隆抗体及其用途
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术（南京）有限公司 抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120039896A1 (en) * 2003-04-24 2012-02-16 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20140141002A1 (en) * 2003-04-24 2014-05-22 The University Of North Carolina At Chapel Hill Method for Inhibiting Cellular Activation by Insulin-Like Growth Factor-1
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HATHERLEY ET AL,, THE STRUCTURE OF THE MACROPHAGE SIGNAL REGULATORY PROTEIN (SIRP ) INHIBITORY RECEPTOR REVEALS A BINDING FACE REMINISCENT OF THAT USED BY T CELL RECEPTORS, 16 March 2007 (2007-03-16) *
LEE ET AL,, NOVEL STRUCTURAL DETERMINANTS ON SIRP ALPHA THAT MEDIATE BINDING TO CD47., 1 January 2007 (2007-01-01) *
LIU ET AL,, FUNCTIONAL ELEMENTS ON SIRP@A IGV DOMAIN MEDIATE CELL SURFACE BINDING TO CD47, 23 December 2006 (2006-12-23) *

Also Published As

Publication number Publication date
ZA201806293B (en) 2023-06-28
NZ746545A (en) 2025-05-30
HUE068840T2 (hu) 2025-01-28
IL262251A (en) 2018-11-29
EP4438626A3 (en) 2024-12-04
HRP20241316T1 (hr) 2024-12-20
JP7549626B2 (ja) 2024-09-11
IL262251B1 (en) 2023-05-01
CN115785272A (zh) 2023-03-14
PH12018550160B1 (en) 2024-07-03
JP7491666B2 (ja) 2024-05-28
US20250215108A1 (en) 2025-07-03
CL2018002898A1 (es) 2018-12-14
FI3443010T3 (fi) 2024-10-10
KR102355240B1 (ko) 2022-01-25
SA518400237B1 (ar) 2025-06-02
US20220281991A1 (en) 2022-09-08
DK3443010T3 (da) 2024-09-30
UA126658C2 (uk) 2023-01-11
US20190127477A1 (en) 2019-05-02
US12252546B2 (en) 2025-03-18
MA44665B1 (fr) 2024-11-29
SI3443010T1 (sl) 2025-01-31
PH12018550160A1 (en) 2019-03-11
US11279766B2 (en) 2022-03-22
SMT202400438T1 (it) 2024-11-15
JP2022169504A (ja) 2022-11-09
KR20180134397A (ko) 2018-12-18
MA44665A (fr) 2019-02-20
JP2019520034A (ja) 2019-07-18
ES2990971T3 (es) 2024-12-02
EP4438626A2 (en) 2024-10-02
LT3443010T (lt) 2024-10-25
PL3443010T3 (pl) 2025-02-03
RS66062B1 (sr) 2024-11-29
MX2018012434A (es) 2019-06-06
MD3443010T2 (ro) 2024-12-31

Similar Documents

Publication Publication Date Title
EP3443010B1 (en) New anti-sirpa antibodies and their therapeutic applications
US12252546B2 (en) Anti-SIRPa antibodies and their therapeutic applications
US11713356B2 (en) Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
US12331115B2 (en) Uses of anti-SIRPg antibodies
HK40113048A (en) New anti-sirpa antibodies and their therapeutic applications
HK40001691B (en) New anti-sirpa antibodies and their therapeutic applications
HK40001691A (en) New anti-sirpa antibodies and their therapeutic applications
EA044391B1 (ru) АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ